Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs.

Andrès E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Séverac F, Tebacher M, Gottenberg JE, Weber JC, Kaltenbach G, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

J Clin Med. 2017 Sep 26;6(10). pii: E92. doi: 10.3390/jcm6100092.

2.

History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort.

Andrès E, Mourot-Cottet R, Maloisel F, Vogel T, Tebacher M, Gottenberg JE.

Eur J Intern Med. 2017 Dec;46:e13-e14. doi: 10.1016/j.ejim.2017.08.018. Epub 2017 Aug 18. No abstract available.

PMID:
28823525
3.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

4.

Idiosyncratic drug-induced neutropenia & agranulocytosis.

Andrès E, Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

QJM. 2017 Jan 9. pii: hcw220. doi: 10.1093/qjmed/hcw220. [Epub ahead of print]

PMID:
28069912
5.

Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases.

Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R, Andrès E.

Drugs Real World Outcomes. 2016 Dec;3(4):393-399.

6.

Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.

Etienne G, Huguet F, Guerci-Bresler A, Nicolini FE, Maloisel F, Coiteux V, Dauriac C, Carpentier N, Bourdeix I, Tulliez M, Cony-Makhoul P.

Br J Haematol. 2016 Jul;174(1):71-80. doi: 10.1111/bjh.14022. Epub 2016 Apr 7.

PMID:
27060881
7.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

Herbaux C, Duployez N, Badens C, Poret N, Gardin C, Decamp M, Eclache V, Daliphard S, Murati A, Cony-Makhoul P, Cheze S, Beve B, Lacoste C, Prebet T, Hunault-Berger M, Maloisel F, Renneville A, Figeac M, Stamatoullas-Bastard A, Bastard C, Fenaux P, Preudhomme C, Rose C; GFM (Groupe Francophone des Myelodysplasies).

Am J Hematol. 2015 Aug;90(8):737-8. doi: 10.1002/ajh.24073.

8.

Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases.

Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A.

Ann Hematol. 2015 Jan;94(1):89-95. doi: 10.1007/s00277-014-2175-0. Epub 2014 Sep 7.

PMID:
25195120
9.

BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.

Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, Maloisel F, Mouysset JL, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H; ORHEO study group.

BMC Cancer. 2014 Jul 10;14:503. doi: 10.1186/1471-2407-14-503. Erratum in: BMC Cancer. 2014;14:720.

10.

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X; French Society of Haematology.

Ann Hematol. 2014 Dec;93(12):1977-83. doi: 10.1007/s00277-014-2140-y. Epub 2014 Jul 5.

11.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ.

Blood. 2014 Jun 26;123(26):4136-42. doi: 10.1182/blood-2013-12-546374. Epub 2014 May 15. Erratum in: Blood. 2014 Aug 14;124(7):1201.

12.

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C.

BMC Cancer. 2013 Nov 16;13:547. doi: 10.1186/1471-2407-13-547.

13.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.

Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M, Decaux O, Eisemann JC, Fitoussi O, Lioure B, Voillat L, Slama B, Al Jijakli A, Benramdane R, Chaleteix C, Costello R, Thyss A, Mathiot C, Boyle E, Maloisel F, Stoppa AM, Kolb B, Michallet M, Lamblin A, Natta P, Facon T, Elalamy I, Fermand JP, Moreau P.

Thromb Haemost. 2013 Oct;110(4):844-51. doi: 10.1160/TH13-02-0140. Epub 2013 Aug 1.

PMID:
23903204
14.

[Ciprofloxacin-induced thrombopenia].

Santucci R, Bouayad-Agha K, Maloisel F, Couturier F.

Med Mal Infect. 2012 Apr;42(4):175-6. doi: 10.1016/j.medmal.2012.02.008. Epub 2012 Apr 3. French. No abstract available.

PMID:
22475418
15.

Gender-related analysis of the clinical presentation, treatment response and outcome in patients with immune thrombocytopenia.

Andrès E, Mecili M, Fothergill H, Zimmer J, Vogel T, Maloisel F.

Presse Med. 2012 Sep;41(9 Pt 1):e426-31. doi: 10.1016/j.lpm.2012.02.010. Epub 2012 Mar 28.

PMID:
22459990
16.

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM).

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4.

PMID:
22023551
17.

Clinical presentation and management of drug-induced agranulocytosis.

Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F.

Expert Rev Hematol. 2011 Apr;4(2):143-51. doi: 10.1586/ehm.11.12.

PMID:
21495924
18.

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC.

Sutton L, Chevret S, Tournilhac O, Diviné M, Leblond V, Corront B, Leprêtre S, Eghbali H, Van Den Neste E, Michallet M, Maloisel F, Bouabdallah K, Decaudin D, Berthou C, Brice P, Gonzalez H, Chapiro E, Radford-Weiss I, Leporrier N, Maloum K, Nguyen-Khac F, Davi F, Lejeune J, Merle-Béral H, Leporrier M; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC).

Blood. 2011 Jun 9;117(23):6109-19. doi: 10.1182/blood-2010-11-317073. Epub 2011 Mar 15.

19.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

20.

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P.

J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.

PMID:
20823406
21.

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.

Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R.

Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25.

PMID:
20738307
22.

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M.

Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3.

PMID:
20605207
23.

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H.

Cancer. 2010 Aug 15;116(16):3852-61. doi: 10.1002/cncr.25123.

24.

The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis.

Andrès E, Maloisel F, Zimmer J.

Br J Haematol. 2010 Jul;150(1):3-8. doi: 10.1111/j.1365-2141.2010.08104.x. Epub 2010 Feb 11. Review.

PMID:
20151980
25.

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L.

J Clin Oncol. 2009 Jun 1;27(16):2668-76. doi: 10.1200/JCO.2008.18.4119. Epub 2009 May 4.

PMID:
19414681
26.

Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center.

Daou S, Federici L, Zimmer J, Maloisel F, Serraj K, Andrès E.

Eur J Intern Med. 2008 Oct;19(6):447-51. doi: 10.1016/j.ejim.2007.07.006. Epub 2008 Feb 20.

PMID:
18848179
27.

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.

Cazin B, Divine M, Leprêtre S, Travade P, Tournilhac O, Delmer A, Jaubert J, Feugier P, Dreyfus B, Mahé B, Grosbois B, Maloisel F, Eghbali H, Dumontet C, Bénichou J, Guibon O, Leleu X, Leporrier M, Maloum K.

Br J Haematol. 2008 Oct;143(1):54-9. doi: 10.1111/j.1365-2141.2008.07309.x. Epub 2008 Aug 15.

PMID:
18710390
28.

[Idiosyncratic drug-induced agranulocytosis].

Federici L, Weitten T, Alt M, Blaison G, Zamfir A, Audhuy B, Maloisel F, Andrès E.

Presse Med. 2008 Sep;37(9):1327-33. doi: 10.1016/j.lpm.2008.03.013. Epub 2008 Jul 17. Review. French.

PMID:
18644319
29.

[Thrombocytopenia during pregnancy: from etiologic diagnosis to therapeutic management].

Federici L, Serraj K, Maloisel F, Andrès E.

Presse Med. 2008 Sep;37(9):1299-307. doi: 10.1016/j.lpm.2007.05.045. Epub 2008 Jul 14. Review. French.

PMID:
18621503
30.

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, List A.

Leukemia. 2008 Sep;22(9):1707-11. doi: 10.1038/leu.2008.156. Epub 2008 Jun 12.

PMID:
18548095
31.

Idiosyncratic drug-induced agranulocytosis or acute neutropenia.

Andrès E, Maloisel F.

Curr Opin Hematol. 2008 Jan;15(1):15-21. Review.

PMID:
18043241
32.

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.

Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ, Mahon FX, Lê QH, Michallet M, Roche-Lestienne C, Preudhomme C.

Haematologica. 2007 Sep;92(9):1238-41.

33.

[Drug-induced agranulocytosis in rheumatology. A retrospective study of 12 cases].

Serraj K, Federici L, Maloisel F, Sibilia J, Andrès E.

Ann Biol Clin (Paris). 2007 Jul-Aug;65(4):431-6. French.

34.

[Pancytopenia related to low-dose methotrexate: study of five cases and review of the literature].

Serraj K, Federici L, Maloisel F, Alt M, Andrès E.

Rev Med Interne. 2007 Sep;28(9):584-8. Epub 2007 Apr 12. French.

PMID:
17451848
35.

Review. Clinical pharmacokinetics of bortezomib.

Levêque D, Carvalho MC, Maloisel F.

In Vivo. 2007 Mar-Apr;21(2):273-8. Review.

36.

Management of idiopathic thrombocytopenic purpura in elderly patients.

Andrès E, Daou S, Zimmer J, Federici L, Maloisel F.

Eur J Haematol. 2007 Feb;78(2):175. No abstract available.

PMID:
17313565
37.

Idiosyncratic drug-induced agranulocytosis: Update of an old disorder.

Andrès E, Zimmer J, Affenberger S, Federici L, Alt M, Maloisel F.

Eur J Intern Med. 2006 Dec;17(8):529-35.

PMID:
17142169
38.

[Update of clinical findings in cobalamin deficiency: personal data and review of the literature].

Federici L, Henoun Loukili N, Zimmer J, Affenberger S, Maloisel F, Andrès E.

Rev Med Interne. 2007 Apr;28(4):225-31. Epub 2006 Nov 14. Review. French.

PMID:
17141377
39.

Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group.

J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20.

PMID:
17116939
40.

Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.

Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R.

Br J Haematol. 2006 Sep;134(6):602-12. Epub 2006 Aug 2.

PMID:
16889621
41.

Current hematological findings in cobalamin deficiency. A study of 201 consecutive patients with documented cobalamin deficiency.

Andrès E, Affenberger S, Zimmer J, Vinzio S, Grosu D, Pistol G, Maloisel F, Weitten T, Kaltenbach G, Blicklé JF.

Clin Lab Haematol. 2006 Feb;28(1):50-6.

PMID:
16430460
42.

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P.

Blood. 2006 May 1;107(9):3474-80. Epub 2006 Jan 5.

43.

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L, Fenaux P; European APL Group; PETHEMA Group.

Leukemia. 2006 Jan;20(1):35-41.

PMID:
16307026
44.

Food-cobalamin malabsorption in elderly patients: clinical manifestations and treatment.

Andrès E, Affenberger S, Vinzio S, Kurtz JE, Noel E, Kaltenbach G, Maloisel F, Schlienger JL, Blicklé JF.

Am J Med. 2005 Oct;118(10):1154-9.

PMID:
16194648
45.

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, Harousseau JL, Eschard JP, Ferrant A, Blanc M, Maloisel F, Orfeuvre H, Rossi JF, Azaïs I, Monconduit M, Collet P, Anglaret B, Yakoub-Agha I, Wetterwald M, Eghbali H, Vekemans MC, Maisonneuve H, Troncy J, Grosbois B, Doyen C, Thyss A, Jaubert J, Casassus P, Thielemans B, Bataille R; Intergroupe Francophone du Myélome (IFM) group.

Blood. 2006 Feb 15;107(4):1292-8. Epub 2005 Sep 20.

46.

Isolated lytic bone lesion as extramedullary disease in chronic myelogenous leukemia: a report of three new cases.

Maloisel F, Favre G, Mahmal L, Zamfir A, Andrès E.

Eur J Intern Med. 2005 Aug;16(4):288-90.

PMID:
16084356
47.

[Idiosyncratic drug-induced agranulocytosis].

Andrès E, Maloisel F; Groupe d'Etude des Agranulocytoses Médicamenteuses des Hôpitaux Universitaires de Strasbourg.

Rev Med Interne. 2006 Mar;27(3):209-14. Epub 2005 Jul 25. Review. French.

PMID:
16043267
48.

Granulocyte-Colony Stimulating Factor (G-CSF) Therapy in Antithyroid Drug-induced Agranulocytosis.

Andrès E, Maloisel F.

Endocr J. 2005 Jun;52(3):383. No abstract available.

49.

Clinical pharmacokinetics of imatinib mesylate.

Levêque D, Maloisel F.

In Vivo. 2005 Jan-Feb;19(1):77-84. Review.

50.

[Agranulocytosis induced by loxapine in an elderly patient: a case study].

Hehn M, Labrune O, Degouy A, Duchene F, Laroche M, Maloisel F, Simon G, Kantelip JP.

Therapie. 2004 Sep-Oct;59(5):561-4. French. No abstract available.

PMID:
15648311

Supplemental Content

Loading ...
Support Center